pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-433 |
Genomic Coordinates | chr14: 100881886 - 100881978 |
Synonyms | MIRN433, hsa-mir-433, miRNA433, MIR433 |
Description | Homo sapiens miR-433 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-433-3p | ||||||||||||
Sequence | 64| AUCAUGAUGGGCUCCUCGGUGU |85 | ||||||||||||
Evidence | Experimental | ||||||||||||
Experiments | Cloned | DRVs in miRNA |
|
||||||||||
SNPs in miRNA |
|
||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | SCAMP1 | ||||||||||||||||||||
Synonyms | SCAMP, SCAMP37 | ||||||||||||||||||||
Description | secretory carrier membrane protein 1 | ||||||||||||||||||||
Transcript | NM_004866 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on SCAMP1 | |||||||||||||||||||||
3'UTR of SCAMP1 (miRNA target sites are highlighted) |
>SCAMP1|NM_004866|3'UTR 1 GAATCTTCAAACAATACACTGTTACCTTTTGACTGTACCTTTTTCTCCAGTTACTGTATTCTACAAATATTTTTATGTTC 81 AAAACACACAGTACAGACAGCATGGATATTTCCTGTTCACTTGTGCATGGGCTAAAACCAGGAAAACTTCCTTGTCTTAT 161 TACTTTACCTAATAGTTTCTTAATATTTCAGTGCCCCTTGCAGAAAAAATATTACATGCTAAATAAATATTCTCCATATT 241 TTTGGGGGATGACATTCAGTGAATTATTTCAGTGGTGACCCACTGAAAATTAATAATGGTACTTATGATTAAAAACGCAT 321 TTAATACTAACTGCAGTAGTTCTTTCAAGAATCTTTAGAGATAAGGATTGCACATTGGAAAAGTAAACCATGTTTCATTC 401 CTTTTTCCCTATTTATATTGAAAGAAATAGGCCAGCAGAGACTTAGGGATTTTAAATTGGCTTGCTTTTTAGCTGTTTCA 481 GTCACCAGTGAAGAGCCTATGTGCATTTTGTAGTAGATAATGTAAAATTTGTCATCTTTTTCTTTTCTTTTTTTTAGAAT 561 AGCTGATATTTTGATAACAATCTCTAATTTGCATGGGCACCACATTTCTTATATTAAAAGAATTAGTGTTTTGGCTTCTG 641 TACTGCTTATGGTTGTAGGATTCAGGGGTTAATGGAATCACAGAAATGATATTCTGCAAGAATTTCTTTTAAATAAAAAG 721 TTTGGGGGTGCAATATAAGAAGTTTATATAATATGCAGTACATTATCCAAAAGAGAAGGTAGTTAATGCAGTAGAAAGTA 801 GTGGTAATAATTCCTTTTTAAAAAAATTTCGGTAGTCATATAGTAACATTTTGCTATATGAAAACTTTGGTATATTCTGT 881 GGTTACAACTAAGATTGTGTCTGGCAGCTCTTTTTTGGGGATGTGTGTGTGTGATTTTTAACAGAGGTATTAAAGGCTAG 961 CCTAACTGTTGTCTAAAAAGATTGTACAGTATTTAAGGGATTTTCCTTTTAGCTTTTCATCTCCAGTGGCATTAAACATA 1041 AAAAGACCCTGGCATTTTTTCACATACTTGAATCCCTAAATGCACCTGTCTTTCACTTTTTGAGACAGACTGAATATATC 1121 TAAAATTTCCAGCAATAAAAAAAAAAGCATTTAACTTGCACCAAGCAAGAAAATATAAATACAGTTAACTGCATTAAGAT 1201 AATCACGTTAAAATTGTTACTATGCAGCACAGAACTTCATTCTTATAGTATTCTTGGGTTCAACCTTTGAATCAATTTTA 1281 CCACTGATTAAATAAATGACTCAAAGACATCTGTAAGTCATGCTGCTGTGTTTTGAAAGTCTTTAACTAAATTAAGATTG 1361 CAGAATGATAGTGATTATTCAATTAGATTTTAAGTAAGGATTGTGATATTAGAGGCTGGAAATCCTTATTTTTTAAAAAA 1441 TCAGATAGGCATAAATAGTTAAATCACTTTCATTCTCCCCAAACCTGTAGTTACAGAAAAAGTTTTATGCTAGAGGTGGG 1521 ATGCCAAGTTTTCACTATCCATGAAGCAGCGCTGCATGTCACTAGGTAACACAGATCCATCCAGATGGTGTTTACATTTG 1601 ATTTATTTGGGATCTTATTGACATCAGGTATACTTGGAAGACATTTCTTTTATTCTTCAGCGTATGAATTTAAAGCTATT 1681 TTTTGTAAATATTTCTAATCAGCGATAATTTCTACCTATGTTCTCAACCAACTTAGCCAGTTTGTTTTTCAGAGCCTGTA 1761 GTCTTATTGGAAATCTATTTTATCAGTGTGCTTTATTGAGTGTGGATTTTGCATACATTCAAAACATTAACCACAAAATA 1841 CAGCAAGTGCACCTATATTCACCATTAACTTATATCCCAAGTCCATTTTTTCCTGTACACTACAAACAAAAGATATATTA 1921 GAGACTTTTGAAAAATGCTGAAATACTTTGCTTCAGAATTGGAATGTTTATATTATGTAGAAATCTTCAAAGGTAGCATT 2001 ATTAAATAGCAAAGAATAATTAGAACCCACATATCTTTTTTTGTGTGGATGGGGAAAATGTTTTAAAATCCAGTTATTTA 2081 ATATGAGTTTGAGAGAGAAAATTGTTTTTTAAAAATATATGTGCATTGAAATGATGGCAATGCTTATAGTATGATCAAGT 2161 ATGAAAGGAACTTTAAATTCTTATATTTACTTTTCTCTCAGTAAATTGTTAAATTTTCACTCAGCAAAAGATTGGCATTT 2241 GTTAAGTGTTCTATATTTAGTACTAAAATCACAGTCATGAAATCATAGTCATAAAATGGTCTTCACACAGCAGTCATCCG 2321 TGTCATTTATCATTTTGTAATATTAAATTATGGCAATTTTATTTCAAACTAAAGTTTGAACACCGGAAAGTCATTACTCA 2401 GTGATTTGTAATTTGGGACTTGGATTATTTATCTAGAGATGTTTGTATATTTTGTCAGTAACTAATACTGCGCTGCCATC 2481 ATGGTGACTGTCATGGTTCTACAGAAATGCCCTCCATGTGTCCCTCTAATGTTGCATGTTTCAGTGGGTTGGAAGTTTTG 2561 TATATTTATTGTATTAACACAGAGTGTCATAAAATAAAATGCTGTTTACTGGATGTTTGTTTGTATAATTTTGAACACTA 2641 TAATAGCAATTCAGAGACAGACATTGTTAAAGGTTTGATGTATATAGAAATTCCATGTTTGATTTTTTAAAATATGTGTA 2721 TAAGTCTGTCATGTGCTAAACAAAATAATATGAAAGACCTAGTTAAAAATTCTAACCAATGTAAAATGACCATTTTTCTG 2801 TTGCATTAGACCTTTACAGGTAATGGAACATGAGCTTCACCCATATTAAATATTTTGGCCCCTTTAAGGTCAAAATACAG 2881 ATCATCTAGAAGTTAGATTCAAAATGGAAAACCTATTCATGGCTCAGATTTTTCATTGTGGGTTAAAAATGGGTGTCTCT 2961 GTACTAGTATTGTATTTATTCAATTGAACTTGTATTCTGATTTCTATCCTTGCTACCTATTGCTGTTTTATGTACTGATG 3041 AAAGTACCTATTTGTGTATATTGGATTTTTCACTTGGTTAGCTAAAGAAGATGTAAAAATATCTAAAATAATGTTCATGG 3121 TGAATCTTATTTTGAGAAATACATGTTAAAAAAGGAACAGTATTCTTTATTTTCTGGGTGTTATATTTAAAAAAGCAAGT 3201 TTGGATTTTTACACCTAATTTACTAGGAAAATATTTTATTCTGTAATTCATGTTAAGATTATGTATGGTTTGCATTTTAA 3281 GGGGATTTATGTTAGGTTAATTAGTTGTTTCTGTAAATCATTTGTAATAGCATAGTGCTTTTTACTCATTGCTGTATCTT 3361 TTTCTGAAAACACTGTTGTTAACATCTAATTCAGTATCCTTATTGGTACAAATCTGTGTTTGGCATGACTGTTTATATAC 3441 AGAATTTGTTACATTTTGAGCATTTTTTCCCCTGCTTATGTATACCTTAGAGTTACCATGGCTGTCATATACCATTTCAC 3521 TATATCTCCTTTCAGTTTTTCCTTAAGGAAAATGTTTAGAGGAATTTGTTCATTTCATGTGATTAAGCCCTTTAGAGATG 3601 AAATAAGATTGGTTAATTTTAAAAAAATTGAGGATGGTTAAAAAATAGAAAACACCTTACTTTGATACATTTTAAAGTAC 3681 AATAGTATACATTTATTTAGAGTAGACTAATGTGTTTAAAACATGAGTTGTTTTAAATACTTTTTTATTGAGCTAAAAAG 3761 TTTTATCTCACATATTAAGTATTACAGAAAGTGAAGTATTTTGGCTAGAATTTTAGGGCATATTTTATAAAGCAGCATGC 3841 CTGTAATATTGGTGGGTATTTTTAAACTTTAGGACTTTATCACAGTATGTAGAGAGCTAGAAATAAATCTAGAAACTTTC 3921 TAAGCCAGGTATTGCCACTAACCTGTCTTATATAAGCAGATACCTCTTATTTGAAGATTGTAGGAAAATAGAGAAAGACT 4001 GTTCTCCAGTTTTCTCACCCCCGCTGTGGGTTTTATATTTACAATTTAACTTTGGGGTTTGGGTAAGACAAACATTTAAT 4081 GTATAGGATTTTGGCCAGGTGTGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCAAGGTGGGCGGATCACGAGG 4161 TCAGGAGATCGAAACCATCCTGGCTAACATGGTGAAACCCCATCTCTACTAAAAATACAAAAAAAAAATTAGCTGAGCAT 4241 GGTGGCGGGCGCCTGTAGTCCCAGCTACTTGGGAGGCTGAGGCAGGAGAATGACGTGAACCTGGGAGGCGGAGCTTGCAG 4321 TGAGCCGAGATCTCTCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCATCTCAAGAAAAAAAAAAAAGAATTTTC 4401 ATTAGTGCTGGCCGTGTTTCAAATGGCAAGGGAACATGGGAACTATCATGTGGCAATGTAGTGAGTGTTAAACTTTGTGT 4481 TTGTCCAAATCCTGATTTATTTTTCAGTTCATATCTTTCTGGGCTTGACATGGCTGATGGTGTAGCTGAAACCCTCCTAA 4561 CACTAAAAGCCATTTAATCTTTTCTGTAATAGGAGCAGAAAATAGTTAATCATCCACCTAGTAATATAAGATTACTGTGA 4641 ATATTATCTTCTATACATTAAAACAGTTCTAGTTTGTAGAATAATACCATACAAGTTTTATTTTTAAATTCTAGTTATTT 4721 TCAGTGCTTACTTAAATGTAATTCTAGAATTCCTCCACAACTTTTAATATTTTGTATGCCAGTGATTCTCAAGATAAATC 4801 ATGATTGTAGTAGTTGTTACTGTTGGCAGTTTGTAGTAGTATTCAGGTATTTTGGGGATGGGGGAAAACACCAAAAATCA 4881 GTGTCTTTTATCTGGTGATCACTGTGGTATCTACAGTATTCTAGTCTCCTGCACAAAAACTGAACCCACTGGGCCTATGC 4961 ATCCCTCACACTTTTTTTCTAGTATAAAAGCAATACATAATGTGTTGTAGAACAATTAAAAATTCAGAAAGTGATACATG 5041 AGAAAATAAAAATAAATCCTTAATTCTGTCAAAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | BC-1 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM796037. RNA binding protein: AGO2. Condition:4-Thiouridine
PAR-CLIP data was present in GSM796038. RNA binding protein: AGO2. Condition:4-Thiouridine
... - Gottwein E; Corcoran DL; Mukherjee N; et al., 2011, Cell host & microbe. |
Article |
- Gottwein E; Corcoran DL; Mukherjee N; et al. - Cell host & microbe, 2011
Primary effusion lymphoma (PEL) is caused by Kaposi's sarcoma-associated herpesvirus (KSHV) and frequently also harbors Epstein-Barr virus (EBV). The expression of KSHV- and EBV-encoded microRNAs (miRNAs) in PELs suggests a role for these miRNAs in latency and lymphomagenesis. Using PAR-CLIP, a technology which allows the direct and transcriptome-wide identification of miRNA targets, we delineate the target sites for all viral and cellular miRNAs expressed in PEL cell lines. The resulting data set revealed that KSHV miRNAs directly target more than 2000 cellular mRNAs, including many involved in pathways relevant to KSHV pathogenesis. Moreover, 58% of these mRNAs are also targeted by EBV miRNAs, via distinct binding sites. In addition to a known viral analog of cellular miR-155, we show that KSHV encodes a viral miRNA that mimics cellular miR-142-3p function. In summary, this study identifies an extensive list of KSHV miRNA targets, which are likely to influence viral replication and pathogenesis.
LinkOut: [PMID: 22100165]
|
CLIP-seq Support 1 for dataset GSM796037 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | BC-1 / 4-Thiouridine |
Location of target site | ENST00000538629.1 | 3UTR | UCAAGAUAAAUCAUGA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22100165 / GSE32109 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM796038 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | BC-1 / 4-Thiouridine |
Location of target site | ENST00000538629.1 | 3UTR | UCAAGAUAAAUCAUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22100165 / GSE32109 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
75 hsa-miR-433-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT001201 | GRB2 | growth factor receptor bound protein 2 | 3 | 1 | ||||||||
MIRT001741 | FGF20 | fibroblast growth factor 20 | 3 | 1 | ||||||||
MIRT007225 | RUNX2 | runt related transcription factor 2 | 1 | 1 | ||||||||
MIRT007361 | CFTR | cystic fibrosis transmembrane conductance regulator | 1 | 1 | ||||||||
MIRT016630 | HDAC6 | histone deacetylase 6 | 1 | 1 | ||||||||
MIRT053561 | KRAS | KRAS proto-oncogene, GTPase | 3 | 1 | ||||||||
MIRT082022 | COX6B1 | cytochrome c oxidase subunit 6B1 | 2 | 4 | ||||||||
MIRT086929 | CREB1 | cAMP responsive element binding protein 1 | 3 | 1 | ||||||||
MIRT096407 | C5ORF22 | chromosome 5 open reading frame 22 | 2 | 2 | ||||||||
MIRT135569 | SPRYD4 | SPRY domain containing 4 | 2 | 2 | ||||||||
MIRT143520 | CHD9 | chromodomain helicase DNA binding protein 9 | 2 | 2 | ||||||||
MIRT167706 | HIVEP1 | human immunodeficiency virus type I enhancer binding protein 1 | 2 | 8 | ||||||||
MIRT207568 | STARD7 | StAR related lipid transfer domain containing 7 | 2 | 4 | ||||||||
MIRT252052 | WDR45B | WD repeat domain 45B | 2 | 2 | ||||||||
MIRT327787 | YIPF6 | Yip1 domain family member 6 | 2 | 2 | ||||||||
MIRT406144 | SERBP1 | SERPINE1 mRNA binding protein 1 | 2 | 2 | ||||||||
MIRT437355 | GBP2 | guanylate binding protein 2 | 3 | 1 | ||||||||
MIRT438242 | TYMS | thymidylate synthetase | 3 | 1 | ||||||||
MIRT438553 | AZIN1 | antizyme inhibitor 1 | 4 | 1 | ||||||||
MIRT444186 | SCAMP1 | secretory carrier membrane protein 1 | 2 | 2 | ||||||||
MIRT477737 | EDN1 | endothelin 1 | 2 | 2 | ||||||||
MIRT483052 | SMU1 | DNA replication regulator and spliceosomal factor | 2 | 2 | ||||||||
MIRT485778 | ATXN1 | ataxin 1 | 2 | 2 | ||||||||
MIRT498142 | FKBP1C | FK506 binding protein 1C | 2 | 4 | ||||||||
MIRT499050 | SSC5D | scavenger receptor cysteine rich family member with 5 domains | 2 | 8 | ||||||||
MIRT501959 | MAPK8 | mitogen-activated protein kinase 8 | 2 | 2 | ||||||||
MIRT503281 | TMEM229B | transmembrane protein 229B | 2 | 4 | ||||||||
MIRT503597 | ZNF780A | zinc finger protein 780A | 2 | 2 | ||||||||
MIRT504577 | UGT2B4 | UDP glucuronosyltransferase family 2 member B4 | 2 | 4 | ||||||||
MIRT506727 | LONRF2 | LON peptidase N-terminal domain and ring finger 2 | 2 | 2 | ||||||||
MIRT523130 | HSP90B1 | heat shock protein 90 beta family member 1 | 2 | 4 | ||||||||
MIRT531338 | TGIF2LX | TGFB induced factor homeobox 2 like, X-linked | 2 | 2 | ||||||||
MIRT534928 | PTPLAD1 | 3-hydroxyacyl-CoA dehydratase 3 | 1 | 1 | ||||||||
MIRT536233 | LRIG3 | leucine rich repeats and immunoglobulin like domains 3 | 2 | 2 | ||||||||
MIRT537092 | GPR135 | G protein-coupled receptor 135 | 2 | 2 | ||||||||
MIRT548286 | FAM3C | family with sequence similarity 3 member C | 2 | 4 | ||||||||
MIRT549143 | BRWD1 | bromodomain and WD repeat domain containing 1 | 2 | 2 | ||||||||
MIRT556354 | MAFK | MAF bZIP transcription factor K | 2 | 2 | ||||||||
MIRT557839 | FKBP1A | FK506 binding protein 1A | 2 | 2 | ||||||||
MIRT564080 | NSA2 | NSA2, ribosome biogenesis homolog | 2 | 2 | ||||||||
MIRT566382 | PLEKHA1 | pleckstrin homology domain containing A1 | 2 | 2 | ||||||||
MIRT573110 | ERBB2IP | erbb2 interacting protein | 2 | 2 | ||||||||
MIRT574403 | TFAP2A | transcription factor AP-2 alpha | 2 | 2 | ||||||||
MIRT576063 | Poteg | POTE ankyrin domain family, member G | 2 | 2 | ||||||||
MIRT619449 | TCF20 | transcription factor 20 | 2 | 2 | ||||||||
MIRT632928 | FGF9 | fibroblast growth factor 9 | 2 | 2 | ||||||||
MIRT633216 | ZNF584 | zinc finger protein 584 | 2 | 2 | ||||||||
MIRT633654 | SLC28A1 | solute carrier family 28 member 1 | 2 | 2 | ||||||||
MIRT637198 | KLHL4 | kelch like family member 4 | 2 | 2 | ||||||||
MIRT646480 | SPATS2L | spermatogenesis associated serine rich 2 like | 2 | 2 | ||||||||
MIRT648314 | SCNN1G | sodium channel epithelial 1 gamma subunit | 2 | 2 | ||||||||
MIRT648631 | LEMD2 | LEM domain containing 2 | 2 | 2 | ||||||||
MIRT655902 | NEK9 | NIMA related kinase 9 | 2 | 2 | ||||||||
MIRT667805 | ITIH5 | inter-alpha-trypsin inhibitor heavy chain family member 5 | 2 | 2 | ||||||||
MIRT675464 | NUBPL | nucleotide binding protein like | 2 | 2 | ||||||||
MIRT675974 | FAM126B | family with sequence similarity 126 member B | 2 | 2 | ||||||||
MIRT676145 | ALDOA | aldolase, fructose-bisphosphate A | 2 | 2 | ||||||||
MIRT676895 | GABPB1 | GA binding protein transcription factor beta subunit 1 | 2 | 2 | ||||||||
MIRT677459 | PDLIM3 | PDZ and LIM domain 3 | 2 | 2 | ||||||||
MIRT677533 | TM4SF5 | transmembrane 4 L six family member 5 | 2 | 2 | ||||||||
MIRT677641 | HAUS2 | HAUS augmin like complex subunit 2 | 2 | 2 | ||||||||
MIRT678806 | HRH4 | histamine receptor H4 | 2 | 2 | ||||||||
MIRT679693 | SLC1A5 | solute carrier family 1 member 5 | 2 | 4 | ||||||||
MIRT679707 | RPL24 | ribosomal protein L24 | 2 | 2 | ||||||||
MIRT698822 | STK38 | serine/threonine kinase 38 | 2 | 2 | ||||||||
MIRT701796 | MRPS25 | mitochondrial ribosomal protein S25 | 2 | 2 | ||||||||
MIRT702220 | LONRF3 | LON peptidase N-terminal domain and ring finger 3 | 2 | 2 | ||||||||
MIRT706095 | ENTPD4 | ectonucleoside triphosphate diphosphohydrolase 4 | 2 | 2 | ||||||||
MIRT706502 | MTMR9 | myotubularin related protein 9 | 2 | 2 | ||||||||
MIRT709780 | NINJ1 | ninjurin 1 | 2 | 2 | ||||||||
MIRT713859 | MBNL1 | muscleblind like splicing regulator 1 | 2 | 2 | ||||||||
MIRT715807 | BBS2 | Bardet-Biedl syndrome 2 | 2 | 2 | ||||||||
MIRT724229 | DGKE | diacylglycerol kinase epsilon | 2 | 2 | ||||||||
MIRT731338 | MET | MET proto-oncogene, receptor tyrosine kinase | 1 | 1 | ||||||||
MIRT731849 | HIF1A | hypoxia inducible factor 1 alpha subunit | 3 | 1 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|